Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its Anti-diabetic products include Gliclazide 80 mg, Tablets, Gliclazide 30 mg, Tablets, Glimepiride 1, 2, 3, 4 mg, Tablets, and others. Its dermatologic therapy products include Macrotor, Ahaglow S Facewash, Fungicide Lotion, Hairjoy 2%, New Dewsoft Cream, Lookbrite 20GMS, Cortaz NC, Dermanex, and others. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.
Torrent Pharmaceuticals Financial Highlights
- Revenue: Torrent Pharmaceuticals reported revenue of ₹13,886.00 crore in FY26 vs ₹11,539.00 crore in FY25. It showed an increase of 20.34% on a yearly basis.
- Operating Profit: Torrent Pharmaceuticals reported an operating profit of ₹2,872.00 crore in FY26 vs ₹2,673.00 crore in FY25. It showed an increase of 7.44% on a year-on-year basis.
- Net Profit: Torrent Pharmaceuticals reported a net profit of ₹2,138.00 crore in FY26 vs ₹1,911.00 crore in FY25. It showed an increase of 11.88% on a yearly basis.
Torrent Pharmaceuticals Quarterly Result Highlights
- Torrent Pharmaceuticals reported revenue of ₹4,180.00 crore in Mar 2026, compared with ₹3,290.00 crore in Dec 2025, representing an increase of 27.05% on a quarter-on-quarter (QoQ) basis.
- Torrent Pharmaceuticals reported an operating profit of ₹529.00 crore in Mar 2026, compared with ₹814.00 crore in Dec 2025, representing a decrease of 35.01% on a quarter-on-quarter (QoQ) basis.
- Torrent Pharmaceuticals reported a profit of ₹364.00 crore in Mar 2026, compared with ₹635.00 crore in Dec 2025, reflecting a decrease of 42.68% on a QoQ basis.
- The earnings per share (EPS) of Torrent Pharmaceuticals stood at ₹63.92 during Mar 2026.
